Table 3.

Summary of safety

Characteristic	Value for patient group (n)		P
	ETV+ADV (45)	LAM+ADV (45)
Any adverse event, no. (%)	23 (51.1)	22 (48.9)	0.83
Serious adverse event, no. (%)	2 (4.4)	2 (4.4)	1.00
Dose reduction of study medication, no.	0	0
Discontinuation of study medication, no.	0	0
ALT flarea	0	0
Increase in serum creatinineb	0	0
Serum creatinine (mg/dl) at wk 52, median (range)	0.9 (0.6-1.5)	0.9 (0.6-1.3)	0.29
Serum phosphorus (mg/dl) at wk 52, median (range)	3.4 (1.6-4.6)	3.3 (2.1-4.4)	0.40
Serum lactic acid (mmol/liter) at wk 52, median (range)	1.3 (0.4-4.0)	1.2 (0.5-2.7)	0.63

^aALT of >10× ULN.

^bValue of ≥0.5 mg/dl above baseline.